Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.43 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18197063 | 0.91 | MAPK1 (0.42) | MAPK1PDPK1MAPK3MAP2K2MAP2K1 | |
| SCHEMBL173256 | 0.90 | MAPK1 (0.53) | MAPK1PDPK1MAPK3MAP2K2MAP2K1 | |
| SCHEMBL173759 | 0.90 | MAPK1 (0.56) | MAPK1PDPK1MAPK3MAP2K2MAP2K1 | |
| SCHEMBL15021911 | 0.89 | MAPK1 (0.51) | MAPK1PDPK1MAPK3MAP2K2MAP2K1 | |
| SCHEMBL15021943 | 0.88 | MAPK1 (0.53) | MAPK1PDPK1MAPK3MAP2K2MAP2K1 | |
| SCHEMBL176069 | 0.88 | LRRK2 (0.56) | MAPK1PDPK1MAPK3MAP2K2MAP2K1 | |
| SCHEMBL15021853 | 0.87 | MAPK1 (0.54) | MAPK1PDPK1MAPK3MAP2K2MAP2K1 | |
| SCHEMBL15021338 | 0.86 | MAPK1 (0.53) | MAPK1PDPK1MAPK3MAP2K2MAP2K1 | |
| SCHEMBL15021550 | 0.86 | MAPK1 (0.52) | MAPK1PDPK1MAPK3MAP2K2MAP2K1 | |
| SCHEMBL176241 | 0.86 | MAPK1 (0.54) | MAPK1PDPK1MAPK3MAP2K2MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2613782-B1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | claimed |
| US-8946216-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | claimed |
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | claimed |
| EP-2613782-B1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8946216-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946216-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946216-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MAPK3, MAPK1, MAP3K1 | MAPK1 2/4885PDPK1 145/4885MAPK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.